2022
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategies
2018
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer
Hou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCD8-positive T cellsTumor-infiltrating lymphocytesHER2-positive casesLymph node metastasisCytotoxic immune reactionsBreast carcinomaImmune reactionsNode metastasisPD-L1Immune cellsConventional chemotherapyBreast cancerT cellsTissue microarrayHER2-positive invasive breast cancerHER2-positive invasive breast carcinomasHER2-positive breast cancerHER2-positive breast carcinomasTumor cellsPD1/PD-L1 expressionHigh Nottingham gradePD-L1 stainingInvasive breast cancerLower tumor stage